European Psychiatry - Volume 33 - March 2016

741 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S737
He has always chosen male activities and male stereotypes compa-
nies. He has presented preference for cross-dressing from 9 years.
Always felt the sexual attraction for women. He first consulted for
this reason in 1995.
Results It reported favorably to start hormone treatment after
completing the eligibility criteria: > 18 years old; knowledge of the
effects of hormones; and more 3 months documented real-life
experience. The hormone therapy caused the growth of micro-
prolactinoma, which was treated with dopamine agonists until it
disappeared and the cessation of galactorrhea. Testosterone treat-
ment is restarted. Laboratory tests are done every 3 months during
the first year and then, every 6 months.
Conclusions Is the gender disphoria a pathology? The EU recom-
mends a reclassification as no pathological disorders in ICD-11. The
treatment of gender dysphoria is necessary, and there is no rea-
son to postpone it. The main difficulty is the differential diagnosis;
there may be comorbidity with others mental disorders which are
not exclusive (psychotic disorder, OCD, personality disorders and
other disorders of gender identity).
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1215
Primary and secondary
transsexualism, really?
F. Jurysta ∗, G. Hladki
1 Centres Hospitaliers Jolimont Asbl, Psychiatrie, Haine-Saint-Paul,
Belgium
2 ULB, Hôpital Erasme, Centre de Sexologie et des Troubles de
l’Identité du Genre CESTIG, Brussels, Belgium
∗ Corresponding author.
Introduction Transsexualismsuffers fromseveral definitions that
evolve across time. Therefore, some discrepancies appear progres-
sively in regard of evidence-based medicine and psychological
approaches as sexo-analysis.
Objectives In our present study, we test if “primary” or “sec-
ondary” transsexualism defines in accordance with sexo-analysis
definitions will be reliable with the pathology course.
Aims Clarify the definition of transsexualism to obtain a better
understanding of this trouble and perhaps to change psychological
approaches of gender disorders.
Methods Nine transsexual male-to-female (MtF) aged between
25 to 65 were voluntary recruited. They were diagnosed by a
psychiatrist. We adapted the GID scale to measure the lifetime pro-
cess. Descriptive statistics were reported. Results are expressed as
mean ±standard deviation.
Results Age of the group is 41± 12. All subjects were treated by
hormone therapy. One of themwas surgical reassigned. All subjects
reported a persistent feeling to be a woman across their entire life.
None showed a decreased female feeling during a part of their life
or a brutal apparition of this trouble during the adult period.
Conclusions In regards of our preliminary results, we concluded
that secondary transsexualism should be redefined and was prob-
ably induced by sociocultural aspects. Our results are limited by
amount of subjects and should be confirmed by a large population
included MtF and FtM people.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1216
Sex, drugs and enhanced libido
B. Macías ∗, N. Serrano , M. Díaz
Hospital Dr. Rodríguez Lafora, Psiquiatría, Madrid, Spain
∗ Corresponding author.
Introduction Twenty-eight years old male, admitted into a long-
stay unit diagnosed of schizoaffective disorder, who has presented
behavioural disturbances consisted in sexual disinhibition.
Case report Since the patient was 15 years old, he has pre-
sented several behavioural disturbances and erotomanic and
reference delusions, which have not ended even after begin-
ning treatment with clozapine. Nowadays treatment consists
of clozapine 600mg/day, haloperidol 20mg/day, amisulpiride
2000mg/day, olanzapine 30mg/day, ciproterone 50mg/day, val-
proic acid 2300mg/day, clorazepate dipotassium 15mg/day,
lorazepam 7.5mg/day, nevertheless the patient still presents
sexual disinhibition against other patients and staff members
(masturbation, exhibitionism, frotteurism, coprolalia). During
treatment, he has suffered from hyperprolactinaemia, but this
entity did not decrease the patient’s sexual desire.
Discussion Although this patient has been treated with a wide
pharmacologic strategy, it has not been effective, so it should be
highlighted how a mixed approach including also psychotherapy,
could be more useful in controlling the libido.
Conclusions This case is an example of variability among patients
and how antipsychotic drugs and chemical castration are not
always useful for decreasing enhanced sex drive.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1217
Secondary sexual dysfunction with
antidepressant treatment: Study on 50
patients
O.W. Muquebil Ali Al Shaban Rodriguez ∗, S. Ocio León ,
M. Gómez Simón , M.J. Hernández González ,
E. Álvarez de Morales Gómez-Moreno , C. Huergo Lora ,
J.R. López Fernández onzález Suárez
A. Barrio Nespereira Gutiérrez Vázquez u˜nón Gorgojo
1 Centro de Salud Mental Mieres, Psychiatry, Mieres del Camino,
Spain
2 Centro de Salud Mental Mieres, Psychology, Mieres del Camino,
Spain
3 CSM Puerta de la Villa, Psichiatry, Gijón, Spain
4 Hospital Vital Álvarez-Buylla, Psichiatry, Mieres del Camino, Spain
5 CSM Puerta de la Villa, Psycology, Gijón, Spain
6 CSM El Quirinal, Psichiatry, Avilés, Spain
7 Centro de Salud Mieres Sur, Nursing, Mieres del Camino, Spain
∗ Corresponding author.
Introduction The side effects of the various antidepressant drugs
on the sexual field (with very few exceptions) are well known, and
they affect the quality of life in important manners. The incidence
rate, communicated spontaneously by the patient, has been esti-
mated around 10–15%, and can reach amounts of 50–60%with SSRIs
when studied specifically. It has been suggested that these effects
compromise treatment adherence.
Objectives To estimate the incidence and intensity of the side
effects on the sexual field with different antidepressants, as well
as its relationship with treatment adherence.
Methodology Transversal study on 50 patients assisted in medi-
cal consultation. Collection of data in office (October 2014–October
2015).
Administration of survey PRSexDQ-SALSEX. In order to research the
relationship with treatment adherence, one question surveyed the
patient whether he/she had thought about finishing treatment for
this reason.
Results Twenty-nine patients (58% of the sample) presented
some degree of sexual dysfunction. Five individuals (17.2%) com-
municated it spontaneously. Nine individuals (31%) responded that
they did not accept positively the changes in their sexual field, and
they had thought about withdrawing treatment for this reason.